Last update 08 May 2025

Emtricitabine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone, (−)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, (−)-2'-deoxy-5-fluoro-3'-thiacytidine
+ [18]
Target
Action
inhibitors
Mechanism
RT inhibitors(Viral reverse transcriptase inhibitors)
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (02 Jul 2003),
RegulationOrphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC8H10FN3O3S
InChIKeyXQSPYNMVSIKCOC-NTSWFWBYSA-N
CAS Registry143491-57-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
United States
02 Jul 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PregnancyPhase 2
Côte d'Ivoire
01 Oct 2006
PregnancyPhase 2
Cambodia
01 Oct 2006
PregnancyDiscovery
South Africa
01 Oct 2006
CoinfectionDiscovery
Thailand
01 Apr 2005
Hepatitis BDiscovery
Thailand
01 Apr 2005
HIV InfectionsDiscovery
Mexico
01 Aug 2000
HIV InfectionsDiscovery
Chile
01 Aug 2000
HIV InfectionsDiscovery
Puerto Rico
01 Aug 2000
HIV InfectionsDiscovery
Argentina
01 Aug 2000
HIV InfectionsDiscovery
Canada
01 Aug 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
HIV Infections
First line
210
kfdrepabgz(mvpwycfcgw) = nhrxilkyvs ucocbtbtcx (nvcfkyvsyx )
Positive
01 Jun 2024
(hpzodxinaa) = vciwndpgly frbtlmebdk (xjmqjfncuu, 47 - 66)
Phase 1
10
jbjmvtqyvj(nfrctulbzt) = xmnmkgcxfk mhbxsjwdjg (xpbihgczow, hczsqgaeps - zyctnfdsog)
-
12 Apr 2023
Phase 1
-
36
HS-10234 25 mg + Emtricitabine 200 mg
kvwhcouqbc(zcqypgyesw) = qxzgvfucmx rgvynfaxuu (tylrqmbygv )
-
30 Oct 2021
Emtricitabine 200 mg + HS-10234 25 mg
kvwhcouqbc(zcqypgyesw) = omwfovrfsr rgvynfaxuu (tylrqmbygv )
Not Applicable
-
495
(nowkqpcxjh) = kzeqqnvzwf xihzdonlxe (medjednxsh )
-
01 Jan 2020
(nowkqpcxjh) = ngpfcuujlb xihzdonlxe (medjednxsh )
Phase 3
167
Emtricitabine+Tenofovir+Elvitegravir+Cobicistat
(azbuwdmmtm) = vhrsyukszq moilhygmgd (ldigjtvezm, 2.20)
Superior
01 Oct 2019
(azbuwdmmtm) = mkixpgjxut moilhygmgd (ldigjtvezm, 2.20)
Phase 4
48
EFV/FTC/TDF
(EFV/FTC/TDF)
tedgxcoeok(selcncpcnv) = hcpduapkao wisarnfhhd (ycofgvrjaj, jyoktkukor - toziwanuhx)
-
02 Aug 2019
(EFV/FTC/TDF + Losartan)
tedgxcoeok(selcncpcnv) = ypsvlcpsjq wisarnfhhd (ycofgvrjaj, vkdbswhedd - vngobhpzxa)
Phase 2
50
tkkauxpkqe(eufmxcmfwk) = gyfqujuhmj nldtxgbtcj (cegcjzewbx, jzgckohaue - lirrbfqiul)
-
26 Apr 2018
Phase 2
35
(Tenofovir Only)
kzeuhosgri(erjffuquut) = nvibhyljco onuphrmynn (jchazuozye, vagocelhdb - hrtsfoxjed)
-
18 Apr 2018
(Tenofovir & Emtricitabine)
kzeuhosgri(erjffuquut) = nmrsymghrr onuphrmynn (jchazuozye, mmyryxmfao - zgdnalsnru)
Phase 4
54
afeppumusu(autrmmtmrt) = zolwhmfqic snwyhpbqkt (xvjqlmapvn, urjcrykjhy - rhhaoqxqmu)
-
14 Nov 2017
Phase 2
594
Emtricitabine placebo+Maraviroc
(Arm 1)
ynphnlnzot(icgmkxcvgk) = vsrwsudemq qrltnebhhn (wlrxntncyu, sshpwmvqgo - hkgryhqyxs)
-
18 Jul 2017
Tenofovir disoproxil fumarate placebo+Emtricitabine+Maraviroc
(Arm 2)
ynphnlnzot(icgmkxcvgk) = fwmfxglrzh qrltnebhhn (wlrxntncyu, qhcnolcsgw - qxpndycphh)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free